Financing channel feed – Endpoints News

Financing channel feed

With Novartis and Google jumping in, Medicxi unveils a $300M late-stage biotech fund with a transatlantic scope

8 years ago

Top JPMorgan investment banker brings his talents — and connections — to the biotech startup crew on board Flagship

8 years ago

Aileron Therapeutics files for a $69M IPO as new offerings heat up

8 years ago

Takeda-backed Mersana joins the biotech IPO queue with a $75M offering and ambitious plans for ADC tech

8 years ago

BRIEF: Deciphera bags a $52M round to back its cancer drug pipeline work

8 years ago

Scientist-turned-VC: Kevin Bitterman takes his biotech hatching experience to a new role at Atlas

8 years ago

Bicycle Therapeutics banks a $52M B round for the next leg of the long R&D journey ahead

8 years ago

$420M fund comes to LYFE, with plans for a trans-Pacific investment strategy introducing US biotechs to China

8 years ago

Ge Li melds WuXi VC with Frontline, creating an $800M trans-Pacific powerhouse fund now hunting fresh biotech capital

8 years ago

Amgen vet Patrick Baeuerle inspires a $45M round from A-list VCs for a next-gen I/O drug platform

9 years ago

Ge Li’s fast-growing WuXi Biologics sets the stage for a $513M IPO

9 years ago

Zai Lab CEO Samantha Du is raising a $150M biotech fund

9 years ago

Adam Koppel and Jeff Schwartz are done raising capital. Now they have $720M to do some serious deals at Bain

9 years ago

Eli Lilly-backed Symic raises $30M round as it preps for a pivotal trial

9 years ago

Two R&D pros map a PhIII game plan with $65M round and a castoff from Pfizer

9 years ago

Vesalius bags €65M biotech fund while Novartis vet Guidi canvases for a €50M gamble on Italian scientists

9 years ago

Upsized offering delivers $100M payoff to argenx as another biotech joins the IPO parade

9 years ago

G1 Therapeutics joins a growing biotech winners circle with $105M IPO

9 years ago

With a $42M raise and a reverse merger, Synlogic makes a quick flip onto Nasdaq

9 years ago

Genoa Pharma grabs a $62M A round to back its oral IPF drug Aerodone

9 years ago

From Biogen’s buy side to biotech CEO: Josh Mandel-Brehm joins the Polaris family as a serial entrepreneur in the making

9 years ago

Armed with a $435M bankroll, Polaris looks to the next wave of biotech startups

9 years ago

Jeremy Levin joins the biotech IPO rush, gaining $75M for Ovid’s R&D game plan

9 years ago

Two new IPOs -- upsized and over the range -- score $226M and signal a possible comeback for biotech

9 years ago

First page Previous page 139 140 141142143 144 145 Next page Last page